共 50 条
The efficacy and safety of combined chinese herbal medicine and western medicine therapy for COVID-19: a systematic review and meta-analysis
被引:10
|作者:
Li, Lu
[1
,2
,3
,4
]
Xie, Hongliang
[1
,2
]
Wang, Ling
[5
]
Zhang, Aolin
[1
,2
]
Mou, Xuan
[1
,2
]
Lin, Yifan
[5
]
Ma, Hongli
[6
]
Wang, Yu
[6
]
Li, Jian
[6
,7
]
Gao, Jingshu
[6
]
Wang, Chi Chiu
[4
,8
]
Leung, Ping Chung
Fan, Xiaohui
[1
,2
]
Wu, Xiaoke
[6
,9
]
机构:
[1] Zhejiang Univ, Pharmaceut Informat Inst, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[2] Zhejiang Univ, State Key Lab Component Based Chinese Med, Innovat Ctr, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Obstet & Gynecol,Sch Med, Key Lab Reprod Dysfunct Management Zhejiang Prov, Hangzhou 310016, Peoples R China
[4] Chinese Univ Hong, Inst Chinese Med, Shatin, Hong Kong, Peoples R China
[5] Zhejiang Chinese Med Univ, Hangzhou TCM Hosp, Hangzhou 310053, Peoples R China
[6] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Obstet & Gynecol, Harbin 150040, Peoples R China
[7] Guizhou Med Univ, Affiliated Hosp, Dept Obstet & Gynecol, Guiyang 550000, Peoples R China
[8] Zhejiang Chinese Med Univ, Coll Basic Med Sci, Hangzhou 310053, Peoples R China
[9] Harbin Inst Technol, Heilongjiang Prov Hosp, Harbin 150040, Peoples R China
关键词:
Systematic review;
Meta-analysis;
Combined Chinese Herbal Medicine-Western Medicine therapy;
Corona Virus Disease 2019 severity;
D O I:
10.1186/s13020-022-00600-z
中图分类号:
R [医药、卫生];
学科分类号:
10 ;
摘要:
Objective To systematically review the clinical efficacy and safety of Chinese herbal medicine (CHM) with and without Western medicine (WM) for different severity of COVID-19. Methods CNKI, PubMed, Wanfang Database, ClinicalTrails.gov, Embase, ChiCTR and ICTRP were searched from 01 Jan, 2020 to 30 Jun, 2021. Two authors independently assessed all the randomized clinical trials (RCTs) for trial inclusion, data extraction and quality assessment. Meta-analysis was conducted using Review Manager software (RevMan 5.4.1). Evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Primary outcomes included total effectiveness rate. Secondary outcomes included improvements in symptom improvement and total adverse event rate. Different severity of COVID-19 patients was assessed in subgroup analysis. This study was registered with INPLASY, INPLASY202210072. Results 22 high quality RCTs involving 1789 participants were included. There were no trial used CHM alone nor compare placebo or no treatment. Compared with WM, combined CHM and WM (CHM-WM) treatment showed higher total effectiveness rate, lower symptom scores of fever, cough, fatigue, dry throat and pharyngalgia, shorter mean time to viral conversion, better Computerized Tomography (CT) image and blood results, fewer total adverse events and worse conditions (P < 0.05). Subgroup analysis showed that the total effectiveness rate of combined CHM-WM group was significantly higher than WM group, especially for mild and moderate patients. No significant differences in mortality and adverse events were found between combined CHM-WM and WM treatment. No serious adverse events and long-term outcomes were reported. Conclusion Current evidence supported the therapeutic effects and safety of combined CHM-WM treatment on COVID-19, especially for patients with mild and moderate symptoms. Long-term effects of therapy are worthy in further study.
引用
收藏
页数:37
相关论文